Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (79)

Latest Posts

About This Stock More About This Stock
Tuesday Talk: Where Is Santa?
Article By: TalkMarkets DailyTalk
Tuesday, December 20, 2022 5:21 AM EST
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
In this article: T, WBD, LLY, MRK, UNH, REGN, GILD, VRTX, IWM, XBI, ABBV
Read
Market Currents: Why Pick Stocks?
Video By: Joseph Calhoun
Monday, November 28, 2022 7:28 AM EST
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and Alhambra CEO Joe Calhoun make the case.
In this video: IBB, REGN, BIIB, SONY Also: SPX
Watch
New Tensions Between The US And China Provoked Investors To Return To Safe-Haven Assets
Article By: JustMarkets
Wednesday, August 3, 2022 10:00 AM EST
Geopolitical tensions rose higher during the day after Chinese battery giant CATL said it would suspend plans to invest billions of dollars in a new battery plant in the United States because of House Speaker Nancy Pelosi's trip to Taiwan.
In this article: CAT, MET, NTDOY, REGN, EBAY, MRNA, BKNG, UBER, PINS
Read
Small Cap Biotech Stocks Are Trending Well
Article By: Rod Raynovich
Monday, July 18, 2022 4:14 AM EST
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.
In this article: REGN, PACB, EXAS, XBI, MRNA, TDOC, CRSP, ARKG, VCYT
Read
Best Biotech Stocks To Buy In 2022
Article By: Elliottwave Forecast
Tuesday, March 15, 2022 6:42 AM EST
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and pharmaceuticals, genomics, and food and chemical manufacturing.
In this article: BMY, JNJ, PFE, NVAX, REGN, AMGN, VRTX, AXSM, GMAB, RLAY
Read

Latest Tweets for $REGN

No tweets yet!

PARTNER HEADLINES

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments